Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

Feb. 12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
Feb. 12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Published on 01/13/2026 at 11:03 am EST

Reuters

Latest news about Amgen Inc.

Feb. 12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
Feb. 12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE
Feb. 12	European Commission Approves Amgen's UPLIZNA for Generalized Myasthenia Gravis	CI
Feb. 10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
Feb. 06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
Feb. 04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
Feb. 04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT
Feb. 04	Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating	MT
Feb. 04	RBC Raises Price Target on Amgen to $360 From $335, Keeps Outperform Rating	MT
Feb. 04	Morgan Stanley Raises Price Target on Amgen to $309 From $304, Keeps Equalweight Rating	MT
Feb. 03	Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln	RE
Feb. 03	Amgen Inc., Q4 2025 Earnings Call, Feb 03, 2026
Feb. 03	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026	CI
Feb. 03	Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost	DJ
Feb. 03	Amgen Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance	MT

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

Apr. 28 - Q1 2026 Earnings Release (Projected)

More about the company